National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Bulevirtide (Hepcludex®). HTA ID: 22067

Bulevirtide is indicated for chronic hepatitis delta (CHD) infection in plasma (or serum) HDV RNA-positive adult patients with compensated liver disease.

 

NCPE Assessment Process Complete
Rapid review commissioned 06/10/2022
Rapid review completed 10/11/2022
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of bulevirtide compared with the current standard of care.